---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-095472"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T23:07:25.016237+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neumora's NMRA-266 Phase 1 placed on clinical hold by FDA after rabbit convulsion data

## Summary
- FDA placed clinical hold on NMRA-266 Phase 1 trial due to preclinical convulsions in rabbits.
- Approximately 30 participants dosed in study; no convulsions observed in any participant.
- Company working with FDA to evaluate resolving the hold; prior guidance on NMRA-266 withdrawn.
- NMRA-266 is an M4 muscarinic receptor PAM, part of Neumora's M4 PAM franchise.

## SEC filing metadata
- accession: 0001193125-24-095472
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312524095472/0001193125-24-095472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312524095472/d805556d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-095472
- JSON: https://secwatch.observer/filing/0001193125-24-095472.json
- Plain text: https://secwatch.observer/filing/0001193125-24-095472.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.